The following are the confidential treatment for Exhibits found in Elites's November 15, 2010 10-Q filing and pertain directly to the Confidential Disclosure filed with the SEC today. The confidential information that has been withheld from public dissemination pertains to Exhibits 10.6 - 10.9. Exhibit 10.7 should be of specific interest as it is only redacted through June 30, 2011, and focuses specifically on an purchase agreement/asset purchase between Epic Pharma and Elite. Recent Form 4 and 5 SEC filings have indicated that Epic Pharma has increased their position in Elite significantly. Possible Conclusion: The recent Form 4/5's are intrinsically connected to the confidential disclosure and an Elite press release will be released forthwith further delineating said events. Disclosure: All information is contained with public information found within Elite's SEC filing. Long ELTP.
Exhibit 10.6 through December 31, 2015 Exhibit 10.7 through June 30, 2011 Exhibit 10.8 through November 15, 2020 Exhibit 10.9 through November 15, 2020
Below are the aforementioned Exhibits contained in ELTP's November 15, 2010 10-Q This one are the last year 10-Q the exhibit 10-7. 10.7 Purchase Agreement, dated as of September 10, 2010, by and among Epic Pharma LLC and the Company. Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A description of this Asset Purchase Agreement is incorporated by reference to Item 2.01 of the Current Report on Form 8-K, dated September 10, 2010 and filed with SEC on September 16, 2010
Quite possible, but "what" is still the question. Could be anything from more ANDA agreements to reverse merger. We can speculate to the moon but pretty sure a portion of this puzzle will be solved at the end of the month or sooner.